Preventing cardiovascular and cerebrovascular diseases, medical device company CellAegis Devices has received 60 million yuan investment
Release date: 2017-04-05
Recently, CellAegis Devices , a medical device company from Toronto, announced the completion of a $9.5 million (more than 60 million yuan) Series C financing. This round of financing was led by Canada's leading venture capital firm CTI Life Sciences Fund. Other investors include MaRS Catalyst Fund, Broadview Ventures and a number of investors from the United States.
In addition, Dr. Shermaine Tilley, managing partner of CTI Life Sciences Fund, and Christopher Colecchi, managing partner of Broadview Ventures, will join the board of directors of CellAegis Devices.
It is reported that the company will use this round of funds to promote the autoRIC equipment of its products for clinical trials in the United States. AutoRIC is a portable automated Remote Ischemic Conditioning (RIC) processing device.
The concept of ischemic preconditioning was proposed by Dr. CE Murry in the United States in 1986 to stimulate the body's immune system to produce and release endogenous protective substances such as adenosine and bradykinin by performing short-term, non-hazardous ischemic training on the human body. Nitric oxide, etc. (these substances participate in human energy metabolism and myocardial protection) to alleviate the serious damage caused by ischemia and hypoxia in the future.
Distal ischemic adaptation (RIC) is to induce the body to produce tolerance to ischemia and hypoxia through blood flow blockage and reflow stimulation of non-essential organs (such as limbs), so that distant vital organs (heart, brain) , liver, kidney, etc.) to provide a protective mechanism for severely lethal ischemia and hypoxia. Remote ischemic adaptation is an innovative means to prevent and treat ischemic heart and cerebrovascular diseases. It can be used for myocardial infarction, heart surgery, stroke, trauma and organ transplantation, etc., and it can effectively avoid cerebral infarction. Sudden occurrence of cardiovascular and cerebrovascular diseases such as sudden cardiac death.
â–²This autoRIC device schematic (Source: CellAegis official website)
In general, inflating a standard blood pressure cuff can trigger limb ischemia, and CellAegis' autoRIC device enables automated non-invasive remote ischemic training, which can complete 4 cycles of training in 40 minutes. At the same time, the device is easy to carry and can be used in hospitals, ambulances and homes.
In addition, for patients who use the device at home, CellAegis also offers an app called “CRICtrac†that allows patients to communicate with their doctors, get guidance and self-treatment without the need for medical staff to follow up.
Currently, autoRIC equipment has been approved by the Health Canada and the European CE Mark and has been used in trials sponsored by several large researchers to assess its efficacy in reducing clinical events after a heart attack.
â–²CRICtrac mobile phone application schematic (Source: CellAegis official website)
“This round of financing has brought us a lot of support from Canadian and US medical technology investors. We will continue to promote AutoRIC's clinical commercialization process in Canada and Europe, and complete FDA trials to prepare for entering the US market.†CellAegis Mr. Rocky Ganske, CEO, said.
Dr. Shermaine Tilley, managing partner of CTI Life Sciences Fund, said: "CTI Life Sciences Fund is confident in CellAegis that its device autoRIC can significantly improve cardiovascular and other organ damage after an ischemic event such as a heart attack. We expect autoRIC to enter the US as soon as possible through FDA approval."
Reference material
[1] CellAegis Devices Inc. Announces US$9.5 Million Financing To Support Clinical And Regulatory Advancement Of Its autoRIC Device
[2] CellAegis Devices official website
Source: Chuangjianhui
Fla
Fladrafinil CRL-40 941 Bisfluroadrafinil
CRL-40,941 is a molecule similar to adrafinil, and has been shown to be more effective than these two molecules in their indications, with fewer side effects.
Significant positive effects of CRL-40, 941 include improved memory, greater mental clarity, increased ambition, and overall higher levels of mental performance. As it improves focus, it could be used to treat conditions such as ADHD, Alzheimer's and depression. It also has great use in the treatment of sleep disorders, such as insomnia or narcolepsy.
Application Functions:
1. Improve memory
2. Increased learning ability
3. Improve cognitive processing
4. Improve your responsiveness
5. Improve your perception
6. Reduce anxiety
Reduce depression
What is the application of CRL-40 941?
* Applied in the pharmaceutical field.
* Used in the field of cosmetics.
Describe :
99% CAS 90212-80-9 Norootropic Fladrafinil CRL 40 941 CRL-40,941
Product Name
White powder
Product photo :
Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.
Fladrafinil CRL-40 941
Chemical Abstracts Society No.
90212-80-9
Appearance
CRL-40,941 is a molecule similar to adrafinil, and has been shown to be more effective than these two molecules in their indications, with fewer side effects.
Significant positive effects of CRL-40, 941 include improved memory, greater mental clarity, increased ambition, and overall higher levels of mental performance. As it improves focus, it could be used to treat conditions such as ADHD, Alzheimer's and depression. It also has great use in the treatment of sleep disorders, such as insomnia or narcolepsy.
Application Functions:
1. Improve memory
2. Increased learning ability
3. Improve cognitive processing
4. Improve your responsiveness
5. Improve your perception
6. Reduce anxiety
Reduce depression
What is the application of CRL-40 941?
* Applied in the pharmaceutical field.
* Used in the field of cosmetics.
Describe :
99% CAS 90212-80-9 Norootropic Fladrafinil CRL 40 941 CRL-40,941
|
Product Name |
Fladrafinil CRL-40 941 |
|
Chemical Abstracts Society No. |
90212-80-9 |
|
Appearance |
White powder |
Product photo :
Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.
Good Sildenafil,Cosmetic Grade Cabomer 940,Creatine Monohydrate 99%,Gel Polymer Powder
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropics.com